Venture capital and the European biotechnology industry

Venture Capital and the European Biotechnology Industry

Volumn , Issue , 2008, Pages 1-220

  Bains, William ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013781562     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1057/9780230227262     Document Type: Book

References (316)

1. Metcalfe, J.S., Restless capitalism, experimental economics, in New technologybased ventures in the new millennium, W. During, R. Oakey, and M. Kipling, eds 2001, Pergamon: Amsterdam. pp. 4-16.
2. Graham, P., A unified theory of VC suckage http://www.paulgraham.com/venture capital.html (produced by Paul Graham, accessed 24 March 2005).
3. Bains, W., Biotechnology from A to Z. 3rd ed. 2004, Oxford, UK: Oxford University Press. 0-19-852498-6.
4. Smith, J.E., Biotechnology. 3rd ed. 1996, Cambridge, UK: Cambridge University Press.
5. Ratledge, C. and B. Kristiansen, eds Basic Biotechnology. 2nd ed. 2001, Cambridge University Press: Cambridge, UK.
6. Ridley, M., Genome. The autobiography of a species. 1999, London, UK: Fourth Estate.
7. Ernst and Young, Beyond borders: A global perspective - Biotechnology industry report 2006. 2006, Ernst and Young Ltd. (New York, May 2006).
8. Bains, W., Open Source and Biotech. Nature Biotechnology, 2005. 23(9): p. 1046.
9. Mason, C. and R. Harrison, The size of the informal venture capital market in the United Kingdom. Small Business Economics, 2000. 15: pp. 137-148.
10. Bains, W., Failure rates in drug discovery and development: Are we getting any better? Drug Discovery World, 2004. 2004 (Fall): pp. 9-18.
11. Smith, J.G. and V. Fleck, Strategies of new biotechnology firms. Long Range Planning, 1988. 21(3): pp. 51-8.
12. Gompers, P.A. and J. Lerner, The Venture Capital Cycle: 2nd edition. 2004, Cambridge, MA: MIT Press.
13. Sætre, A.S., Entrepreneurial perspectives on informal venture capital. Venture Capital, 2003. 5(1): pp. 71-94.
14. Amis, D. and H. Stevenson, Winning Angels: The seven fundamentals of early stage investing. 2001, London, UK: Prentice Hall.
15. Bradford, T.C., Evolving symbiosis - venture capital and biotechnology. Nature Biotechnology, 2003. 21(9): pp. 983-4.
16. Dibner, M.D., M. Trull, and M. Howell, US Venture capital for biotechnology. Nature Biotechnology, 2003. 21(6): pp. 613-17.
17. Lee, D.P. and M.D. Dibner, The rise of venture capital and biotechnology in the US and Europe. Nature Biotechnology, 2005. 23(6): pp. 672-6.
18. Kenny, M., Biotechnology: The university: Industrial complex. 1986, New Haven: Yale University Press.
19. Martin, P. and S. Thomas, The 'commercialization gap' in gene therapy: Lessons for European competitiveness, in Biotechnology and Competitive Advantage, J. Senker and R. van Vliet, eds 1998, Edward Elgar: Cheltenham, UK. pp. 130-55.
20. Manigart, S., M. Wright, K. Robbie, P. Desbrières, and K. De Waele, Venture capitalists' appraisal of investment projects: An empirical European study. Entrepreneurship Theory and Practice, 1998. 21(4): pp. 29-44.
21. Murray, G.C., Evolution and change: An analysis of the first decade of the UK venture capital industry, in Venture Capital, M. Wright and K. Robbie, eds 1997, Dartmouth: Aldershot, UK. pp. 54-82.
22. Bains, W., How academics can make (extra) money from their science. Journal of Commercial Biotechnology, 2005. 11(4): pp. 1-11.
23. European Investment Fund, Annual Report 2004. 2004, European Investment Fund (Luxembourg).
24. Saviotti, P.P., P. -B. Joly, J. Esrades, S. Ramani, and M. -A. de Looze, The creation of European dedicated biotechnology forms, in Biotechnology and Competitive Advantage, J. Senker and R. van Vliet, eds 1998, Edward Elgar: Cheltenham, UK. pp. 68-88.
25. Tegenero, Tegenero Immuno Therapeutics (website) http://www.tegenero.com/ about_us/index.php (produced by Tegenero, accessed 21/02/2006).
26. Ernst and Young, Biotech 91: A changing environment. 1990, Ernst and Young (SanFrancisco, 1 February. 1990).
27. Ernst and Young, Biotech 97: Alignment. 1996, Ernst and Young (San Francisco, CA, 1 April 1996).
28. Ernst and Young, Integration: Ernst and Young's Eighth annual European life science report 2001. 2002, Ernst and Young (London, 2002).
29. Bioscan database, 1995, AR, USA: Oryx Press.
30. Bioscan database, 1998, AR, USA: Oryx Press.
31. Walsh, G., Biopharmaceutical benchmarks 2006. Nature Biotechnology, 2006. 24(7): pp. 769-76.
32. Lähteenmäki, R. and S. Lawrence, Public Biotechnology 2005 - the numbers. Nature Biotechnology, 2006. 24(6): pp. 625-41.
33. Lawrence, S., Biotech as an employer. Nature Biotechnology, 2007. 25(1): p. 12.
34. Chipman, A., Fatal Attraction. Nature, 2005. 436(7051): pp. 624-5.
35. Johnstone, B., Britain's stake in biotechnology, London Times, (London), 12/11/1980, p 26.
36. Anon, Grand Met puts $10M into genetic engineering, Times of London, (London), 25/3/1980, p. 19.
37. Cookson, C., The investors' honeymoon with biotechnology comes to an end, Times, (London), 25 October 1982, p. 16.
38. Tran, M., Market Marshalls its forces in the battle against AIDS, Guardian, (London), 13 April 1992, p. 11.
39. Global Business Insights, The top ten biotechnology companies. 2005, Global Business Insights, (London, UK).
40. Anon, Synthetic blood clot agent to be produced, Times of London, (London), 24/11/1982, p. 2.
41. Anon, Genetic engineers prepare for battle, Times of London, (London), 21/3/1983, p. 16.
42. Thakor, A.V., Comment on Trester. Journal of Banking and Finance, 1998. 22(6-8): pp. 700-1.
43. Allen, M., Where even the small firm can find finance, London Times, (London), 9/5/1972, p. 6.
44. EVCA, European Venture Capital Association web site http://www.evca.com/ html/home. asp (produced by European Venture Capital Association, accessed February 2007).
45. Wright, P., Genetic engineering's industrial heartland, London Times, (London), 7/8/1981, p. 19.
46. Fairtlough, G., Creative Compartments: A design for future organization. 1994, London, UK: Adamantine Press.
47. Walsh, V., J. Niosi, and P. Mustar, Small firm foundation in biotechnology: A comparison of Britain, France and Canada. Technovation, 1995. 15(5): pp. 303-27.
48. Harding, R., Global Entrepreneurship Survey 2004. 2005, London School of Economics (London).
49. Fishlock, D., Why industry is taking more notice, London Times, (London), 27/12/1984, p. 9.
50. Fishlock, D., The reluctant entrepreneurs, London Times, (London), 4/10/1982, p. 17.
51. Wright, P., Biotechnology: 'Genetic engineering' creates a new industrial revolution, Times, (London), 26 February 1981, p. 4.
52. Mason, C., S. Cooper, and R. Harrison, The role of venture capital in the development of technology clusters: The case of Ottowa, in New technology-based firms in the new millennium, vol II, R. Oakey, W. During, and S. Kauser, eds 2002, Pergamon: Amsterdam. pp. 261-78.
53. Avnimelech, G. and M. Teubal, Venture capital start-up co-evolution and the emergence and development of Israel's high-tech cluster. Econ. Innov. New. Techn., 2004. 13(1): pp. 33-60.
54. Anon, Cleantech firms attracted $1.3bn of global VC investment in 2006, in Freeradicals. 2007. p. 69.
55. Lynn, M., Drug firms seek cash injection abroad, Sunday Times, (London), 7 March 1993, p. 15.
56. Woolcock, K., Bio firms looking abroad for funds, Mail on Sunday, (London), 15 March 1992, p. 74.
57. Arnold, M., IDM's flight a 'wake-up call' for Europe, Financial Times, (London), 21 October 2005, p. 20.
58. Pollack, A., U.S. Finance pulls biotech across seas, New York Times, (New York), 12 July 2006, p. 12.
59. Pollack, A., Europe's Biotech 'immigrants' to America, New York Times, (New York), 11 July 2006, p. 11.
60. Freel, M.S. and P.J.A. Robson, Small firm innovation, growth and performance. International Small Business Journal, 2004. 22(6): pp. 561-75.
61. Harris, D., Fast cash flow that helps industry grow, Times, (London), 10 May 1985, p. 15.
62. Gompers, P.A., Venture capital growing pains: Should the market diet? Journal of Banking and Finance, 1998. 22(6-8): pp. 1089-104.
63. Bains, W., Recognising the value of invention, in IP Review. 2006. p. 6.
64. Atchison, K., Reply to Bains, in IP Review. 2006. p. 6.
65. Bygrave, W., N. Fast, R. Khoylian, L. Vincent, and W. Yue, Early rates of return of 131 venture capital funds started 1978-84. Journal of Business Venturing, 1989. 4(2): pp. 93-105.
66. Manigart, S., P. Joos, and D. DeVos, Performance of publically traded European VC companies, in Frontiers of Entrepreneurial Research, W. Bygrave, et al., eds 1992, Wellesley: Boston, MA.
67. Tyebjee, T.T. and A.V. Bruno, A model of venture capitalist investment activity, in Venture Capital, M. Wright and K. Robbie, eds 1997, Dartmouth: Aldershot, UK. pp. 103-18.
68. AIFC, EVCA, and BVCA, International provate equity and venture capital valuation guidelines. 2006, International Private Equity and Venture Capital valuation Board (Brussels, 7 January 2007).
69. Bains, W., Measurements for Biotechnology: Advice and training. 2007, Measurements for Biotechnology Initiative (LGC/Department of Trade and Industry) (London).
70. Booth, B., Early-stage returns? Nature Biotechnology, 2006. 24(11): pp. 1337-2340.
71. Sahlman, W.A., The structure and governance of venture-capital organizations, in Venture Capital, M. Wright and K. Robbie, eds 1997, Dartmouth: Aldershot, UK. pp. 3-51.
72. 3i Group, 3i Group plc annual report and accounts 2006. 2006, 3i plc (London, UK).
73. GIMV, GIMV annual report 2005. 2006, GIMV (Den Haag, The Netherlands, 2006).
74. Shepherd, J., Wealthy sultans of spin-off cash in on their ideas, Times Higher Educational Supplement, (London), 20 January 2006, pp. 8-9.
75. Count, M., Commercial Breaks for Professors who are not so nutty, London Times, (London), 24/11/2001, pp. 52-3.
76. Edwards, M.G., Academic equity in start-up companies: A retrospective look at Biotech IPOs http://www.recap.com/consulting.nsf/0/7AD3CD2D5E2D3C1788 256FA4005D6596/$FILE/AUTM0205.pdf (produced by Recombinant Capital, accessed 22/4/2005).
77. Gregory, W.D. and T.P. Sheahen, Technology transfer by spin-off companies vs licensing, in University spin-off companies: Economic development, faculty entrepreneurs and technology transfer, A.M. Brett, D.V. Gibson, and R.W. Smilor, eds 1991, Rowman and Littlefield Publishers: Savage, MD, USA. pp. 133-52.
78. Quested, T., Evans steps up Merlin fundraising despite SFO probe www. businessweekly.co.uk (produced by Business Weekly, accessed 12 October 2005).
79. Coombs, J. and Y.R. Alston, The International Biotechnology Directory 1988, Basingstoke: Macmillan Publishers.0-333-43726-8.
80. Deakins, D., Entrepreneurship and Small Firms. 2nd ed. 1999, London: McGraw Hill.
81. DeYoung, G., University and Industry in agreement. Bio/Technology, 1988. 6(8): pp. 906-10.
82. Bunting, S., Life's rich opportunity, Financial Times, (London), 4th July 2002, p. 12.
83. Klausner, A., DNAX keeps a scholar's focus. Bio/Technology, 1988. 6(4): pp. 373-8.
84. Berry, M., UK Managers worst in Europe for staff communication, in Personnel Today 2005. pp. 11-12.
85. Trompenaars, F., Riding the Waves of Culture. 1997, London, UK: Nicholas Brealey.1857881761.
86. Hendry, C. and J. Brown, Local skills and knowledge as critical contributions to the growth of industry clusters in biotech, in New technology-based firms in the new millennium, W. During, R. Oakey, and M. Kipling, eds 2000, Permagon: Oxford. pp. 127-40.
87. Klausner, A., Many angles to competitive analysis. Bio/Technology, 1987. 5(11): p. 1129.
88. Thomas, E., Hamming's 'open doors' and group creativity as keys to scientific excellence: The example of Cambridge. Medical Hypotheses, 2008. 70(3): pp. 473-7.
89. Riquelmo, H. and J. Watson, Do venture capitalists' implicit theories on new business success/failure have empirical validity? International Small Business Journal, 2002. 20(4): pp. 395-420.
90. Dimov, D.P. and D.A. Shepherd, Human capital theory and venture capital firms: Exploring 'home runs' and 'strike outs'. Journal of Business Venturing, 2005. 20(1): pp. 1-21.
91. Powers, J.B. and P.P. McDougall, University start-up formation and technology licensing with firms that go public: A resource-based view of academic entrepreneurship. Journal of Business Venturing, 2005. 20: pp. 291-311.
92. Mitchell, P., Europe caught in innovation quagmire. Nature Biotechnology, 2005. 23(9): p. 1029.
93. Critical I, The equity gap: European and US biotechnology 2001-2. 2004, Bioindustry Association (London).
94. Critical I, Comparative Statistics for the UK, European and US Biotechnololgy sectors: Analysis year 2003. 2005, Department of Trade and Industry (London, February 2005).
95. Bains, W., What you give is what you get: Investment in European biotechnology. Journal of Commercial Biotechnology, 2006. 12(4): pp. 274-83.
96. Hogdson, J., Germany hit badly by investor disinterest. Nature Biotechnology, 2002. 20(6): p. 531.
97. Lawrence, S., Tech transfer - slow progress. Nature Biotechnology, 2005. 23(1): p. 12.
98. Capart, G., Innovation from public research in Europe, in From IP to IPO: Key issues in commercialising university technology (Supplement to Intellectual Property Management magazine), J. Wild, ed. 2005, Intellectual Property Management magazine: London. pp. 8-10.
99. Newmark, P., Low pay, low profits in United Kingdom. Bio/Technology, 1988. 6(3): p. 249.
100. McCormick, D., 1988 compensation survey results. Bio/Technology, 1988. 6(9): pp. 1013-18.
101. Anon, Biotech hamstrung by investment strategies. Chemistry and Industry, 2004. 2004(1): p. 5.
102. Mitchell, P., Next-generation monoclonals less profitable than trailblazers? Nature Biotechnology, 2005. 23(8): p. 906.
103. Wiles, M. and P. Andreassen, Monoclonals: The billion dollar molecules of the future. Drug Discovery World, 2006. 2006 (Fall): pp. 17-23.
104. Kola, I. and J. Landis, Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery, 2004. 3(8): pp. 711-15.
105. Klausner, A., Genentech's busy lawyers. Bio/Technology, 1988. 6(5): p. 472.
106. Klausner, A., Varying views of Genentech's litigation. Bio/Technology, 1988. 6(6): pp. 646-7.
107. Bains, W., Litigation escalates for patents on a chip. Nature Biotechnology, 1997. 15(5): p. 406.
108. Gompers, P.A., Optimal investment, monitoring and the staging of venture capital, in Venture Capital, M. Wright and K. Robbie, eds 1997, Dartmouth: Aldershot, UK. pp. 285-313.
109. Sweeting, R.C., UK Venture capital funds and the funding of new technologybased businesses: Process and relationships, in Venture Capital, M. Wright and K. Robbie, eds 1997, Dartmouth: Aldershot, UK. pp. 316-47.
110. Reichhardt, T., Touched by an angel. Nature, 2005. 435(7043): pp. 734-5.
111. Sheridan, C., German biotech gets a second chance. Nature Biotechnology, 2004. 12(12): pp. 1414-15.
112. Chemistry Leadership Council, Chemical science spin-outs from UK Universities: Review of critical success factors. 2005, Royal Society of Chemistry and the Chemistry Leadership Council (London, UK, 2005).
113. Pearson, S., European Biotechs face a funding crisis. Genetic engineering news, 2006. 26(16): pp. 1-10.
114. Mitchell, P., Could bank loans solve Europe's biotech financing slump. Nature Biotechnology, 2005. 23(12): pp. 1459-60.
115. Murray, G., The second 'Equity Gap': Exit problems for seed and early stage venture capitalists and their investee companies. International Small Business Journal, 1993. 12(4): pp. 59-75.
116. Burnand, A., The Future is Bright, 3 April 2006. pp. 17-19.
117. Anon, The YIC factor. Nature Biotechnology, 2005. 23(10): p. 1187.
118. Library House, The false funding gap. European Venture Capital Journal, 2006. 136: p. 9.
119. Harding, R. and M. Cowling, Assessing the scale of the equity gap. Journal of small business and enterprise development, 2006. 13(1): pp. 115-31.
120. Gray, C., Managing entrepreneurial growth: A question of control?, in Small firms: Entrepreneurship in the nineties, D. Deakins, P. Jennings, and C. Mason, eds 1997, Paul Chapman Publishing: London. pp. 18-28.
121. Gorman, M. and W.A. Sahlman, What do venture capitalists do? Journal of Business Venturing, 1989. 4: pp. 231-48.
122. Lawrence, S., US trails Europe in IPOs. Nature Biotechnology, 2005. 23(10): p. 1195.
123. Moran, N., Technology commercialization firms float in UK - but not elsewhere. Nature Biotechnology, 2007. 25(7): pp. 697-8.
124. Papadopoulos, S., Evolving paradigms in biotech IPO valuations. Nature Biotechnology, 2001. 19(Supplement): pp. BE18-BE19.
125. Burrill, G.S., The beginning of the biotech century? Modern Drug Discovery, 2000. 3(5): pp. 75-6.
126. Lawrence, S., Upward Trend in financing continues, but fewer feel flush. Nature Biotechnology, 2007. 25(1): p. 3.
127. McGully, M.G. Current Trends in Deals and Financing. in GTCbio's Metabolic Diseases World Summit: Partnering and Deal-making summit. 2005. Burlingame, San Francisco, CA, US.
128. Edelson, S., Bye-bye boom and bust. Biocentury, 2006. 14(1): pp. A1-A6.
129. Bains, W., The long-term value of genomics companies. Journal of Chemical technology and biotechnology, 2000. 75: pp. 883-900.
130. Aldridge, S., Business Savvy for UK Biotechs. Genetic engineering news, 2007. 27(2): pp. 12-13.
131. Sheridan, C., Germany biotech gets a second change. Nature Biotechnology, 2003. 21(12): pp. 1414-15.
132. Anon, Merlin chief warns over funding, Daily Telegraph, (London), 13 November 2003, p. 35.
133. Dalal, Y. and S. Orn, Examining an innovative financing alternative for mid-stage biotechs. 2006, Kellogg School of Management (Evanston, IL, Winter 2006).
134. Dyer, G., Biotechnology industry facing funding crisis, Financial Times, (London), 17 November 2003, p. 5.
135. Voison, E., Biotech's comeback in France. Bioprocess international, 2007. Supplement: European Conference: pp. 8-13.
136. Pilling, D., Survey: Life sciences, Financial Times, (London), 28 October 1999, p. 1.
137. Anon, All together now? Nature Biotechnology, 2006. 24(12): p. 1454.
138. Mason, C. and M. Stark, What do investors look for in a business plan? A comparison of the investment criteria of bankers, venture capital and business angels. International Small Business Journal, 2004. 22(3): pp. 227-48.
139. Mason, C. and A. Rogers, The business angel's investment decision: An exploratory analysis, in Small firms: Entrepreneurship in the nineties, D. Deakins, P. Jennings, and C. Mason, eds 1997, Paul Chapman Publishing: London. pp. 29-46.
140. Sahlman, W.A., How to write a great business plan. Harvard Business Review, 1997. 1997 (July-August).
141. Föller, A., Leadership management needs in evolving biotech companies. Nature Biotechnology, 2004. 20 (Bioentrepreneur supplement): pp. BE65-BE66.
142. MacMillan, I.C., L. Zemann, and P.N. Subbanarasimha, Criteria distinguishing successful from unsuccessful ventures in the venture screening process, in Venture Capital, M. Wright and K. Robbie, eds 1997, Dartmouth: Aldershot, UK. pp. 123-33.
143. Cardullo, M.W., Technological entrepreneurism. 1999, Baldock, UK: Research Studies Press.
144. Oakey, R.P., Technical entrepreneurship in high technology small firms: Some observations on the implications for management. Technovation, 2003. 23: pp. 679-88.
145. Walton, A., Some thoughts on bioentrepreneurship. Nature Biotechnology, 1999. 16(Supplement): pp. 7-8.
146. Fletcher, L., Merlin's Maestro. Nature Biotechnology, 2002. 20(Supplement): pp. BE13-BE14.
147. Chandler, G.N. and S.H. Hanks, An examination of the substitutability of founders human capital and financial capital in emerging business ventures. Journal of Business Venturing, 1998. 13: pp. 353-69.
148. Maynard, O. and W. Bains, Share structure and entrepreneurship in UK biotechnology companies: An empirical study. Journal of Commercial Law Studies, 2008. 81(1): pp. 1-37.
149. Fried, J. and M. Ganor, Common stock vulnerability in venture-backed startups. New York University Law Review, 2006 (May 2006).
150. Wyatt, M., A study of the dynamic nature of principle agent relationships within the venture capital industry - based on an analysis of venture capital investing in the UK biotechnology industry in 1999 & 2002, in Executive MBA. 2004, University of Warwick: Coventry.
151. Kanniainen, V. and C. Keuschnigg, Start-up investment with scarce venture capital support. Journal of Banking and Finance, 2004. 28(8): pp. 1935-59.
152. Cyr, L.A., D.E. Johnson, and T.M. Welbourne, Human resources in initial public offering firms: Do venture capitalists make a difference? Entrepreneurship Theory and Practice, 2000. 25(1): pp. 77-91.
153. Loizos, C., The toxic entrepreneurs. Venture Capital Journal, 2005. 2005(April 7): pp. 1-3.
154. Rothwell, R., VC, small firms and public policy in the UK. Research Policy, 1985. 14: pp. 253-65.
155. Manigart, S., K. Baeyens, and W. Van Hyfte, The survival of venture capital backed companies. Venture Capital, 2002. 4(2): pp. 103-24.
156. Busenitz, L.W., J.O. Fiet, and D.D. Moesel, Reconsidering the venture capitalists' 'value added' proposition: An interorganizational learning perspective. Journal of Business Venturing, 2004. 19: pp. 787-807.
157. MacMillan, I.C., D.M. Kulow, and R. Khoylian, Venture capitalists' involvement in their investments: Extent and performance, in Venture Capital, M. Wright and K. Robbie, eds 1997, Dartmouth: Aldershot, UK. pp. 246-65.
158. Aldrich, H.E., A.B. Elam, and P.R. Reese, Strong ties, weak ties and strangers, in Entrepreneurship in a global context, S. Birley and I.C. MacMillan, eds 1997, Routledge: London. pp. 1-25.
159. O'Regan, N., M. Sims, and A. Ghobadian, The impact of management techniques on performances in technology-based firms. Technovation, 2004. 24: pp. 265-73.
160. Barry, C.B., New directions in research on venture capital finance. Financial Management, 1994. 23(3): pp. 3-15.
161. Zider, B., How venture capital works. Harvard Business Review, 1998. 1998 (December).
162. Fletcher, L., Sir Chris Evans, the UK's leading bioentrepreneur, reflects on his evolution from lab rat to financial wizard. Nature Biotechnology, 2002. 20(6): pp. BE13-BE14.
163. Korn/Ferry International, 25th Annual Board of Directors Study. 1998, Los Angeles, CA: Korn Ferry International.
164. Ferris, S.P., M. Jagannathan, and A.C. Pritchard, Too busy to mind the business? Monitoring by directors with multiple board appointments. Journal of Finance, 2003. 58(3): pp. 1087-1111.
165. Ruhnka, J.C., H.D. Feldman, and T.J. Dean, The 'living dead' phenomenon in venture capital investments, in Venture Capital, M. Wright and K. Robbie, eds 1997, Dartmouth: Aldershot, UK. pp. 350-67.
166. Parjankangas, A. and H. Landström, How venture capitalists respond to unmet expectations: The role of social environment. Journal of Business Venturing, 2006. 21: pp. 773-801.
167. Murray, G. and R. Marriot, Modelling the economic viability of an early-stage, technology focussed, venture capital fund, in New technology-based firms in the 1990s, vol 5, R. Oakey and W. During, eds 1998, Paul Chapman Publishing: London. pp. 97-121.
168. Hellmann, T. and M. Puri, Venture capital and the professionalization of startup firms: Empirical evidence. Journal of Finance, 2002. 57(1): pp. 169-97.
169. Boeker, W. and R. Karichalil, Entrepreneurial transitions: Factors influencing founder departure. Acad. Manage. J., 2002. 45(4): pp. 818-26.
170. Bains, W., When should you fire the founder. Journal of Commercial Biotechnology, 2007. 13(3): pp. 139-49.
171. Hambrick, D.C. and L.M. Crozier, Stumblers and start in the management of growth. Journal of Business Venturing, 1985. 1: pp. 31-45.
172. McCarthy, A.M. and D.A. Krueger, Changes in the time allocation patterns of entrepreneurs. Entrepreneurship Theory and Practice, 1990. 15: pp. 7-18.
173. Drucker, P., Innovations and Entrepreneurship. 1985, New York: Harper and Row.
174. Clifford, D.K. and R.E. Cavenaugh, The Winning Performance. 1985, New York: Bantam Books.
175. Carroll, G.R., Dynamics of publisher succession in newspaper organizations. Adm. Sci. Q., 1984. 29: pp. 93-113.
176. Haveman, H.A., Ghosts of managers past: Managerial succession and organizational mortality. Acad. Manage. J., 1993. 36: pp. 864-81.
177. Barth, E., T. Gulbrandsen, and P. Schøne, Family ownership and productivity: The role of owner-management. Journal of Corporate Finance, 2005. 11: pp. 107-27.
178. Smith, B.F. and B. Amoako-Adu, Management succession and financial performance of family controlled firms. Journal of Corporate Finance, 1999. 5: pp. 341-68.
179. McConaughty, D.L., M.C. Walker, G.V. Henderson, and C.S. Mishra, Founding family controlled firms: Efficiency and value. Review of Financial Economics, 1998. 7: pp. 1-19.
180. Barnes, L.B. and S.A. Hershon, Transferring power in the family business. Family Business Review, 1989. 2: pp. 187-202.
181. Granlund, M. and J. Taipaleenmäki, Management control and controllership in new economy firms - a life cycle perspective. Management accounting research, 2005. 16: pp. 21-57.
182. Willard, G.E. and D.A. Krueger, In order to grow, must the founder go: A comparison of performance between founder and non-founder managed high-growth manufacturing firms. Journal of Business Venturing, 1992. 7(3): pp. 181-94.
183. Higashide, H. and S. Birley, The consequences of conflict between the venture capitalist and the entrepreneurial team in the United Kingdom from the perspective of the venture capitalist. Journal of Business Venturing, 2002. 17: pp. 59-81.
184. Florin, J., Is venture capital worth it? Effects on firm performance and founder returns. Journal of Business Venturing, 2005. 20: pp. 113-35.
185. Parker, S.K. and M. Skitmore, Project management turnover: Causes and effects on project performance. International Journal of Project Managament, 2005. 23: pp. 205-14.
186. Edgington, S.M., What went wrong with Centoxin. Bio/Technology, 1992. 10: p. 617.
187. Spalding, B.J., FDA setback flattens Centocor. Bio/Technology, 1992. 10: p. 616.
188. Scarlett, J.A., Biotechnology's emerging opportunities: Lessons from the Bauhaus. Nature Biotechnology, 1999. 17(Supplement): pp. BE13-BE15.
189. Formela, J.-F., Business models for the biotech entrepreneur. Nature Biotechnology, 1999. 16(Supplement): p. 16.
190. Stoiber, W., Consolidation challenges in Europe's life science sector - making it happen. Journal of Commercial Biotechnology, 2003. 10(1): pp. 29-34.
191. Hodgson, J., Crystal gazing the new technologies. Nature Biotechnology, 2000. 18(1): pp. 29-31.
192. Drews, J., Biotechnology's metamorphosis into a drug discovery industry. Nature Biotechnology, 1999. 16(Supplement): pp. 22-4.
193. Papadopoulos, S., Business models in biotech. Nature Biotechnology, 2000. 18(Supplement): pp. IT3-IT4.
194. James, R., Differentiating genomics companies. Nature Biotechnology, 2000. 18(2): pp. 153-55.
195. Bassett, P., Paring down the company: The effect of consolidation in the European biotech sector. Nature Biotechnology, 2003. 21(7): pp. 829-30.
196. Thiel, K.A., Goodbye Columbus! New NRDOs forgo discovery. Nature Biotechnology, 2004. 22(9): pp. 1087-92.
197. Dean, P.M., E.D. Zanders, and D.S. Bailey, Industrial-scale, genomics-based drug design and discovery. Trends in Biotechnology, 2001. 19(8): pp. 288-92.
198. Beeley, L.J. and D.M. Duckworth, The impact of genomics on drug design. Drug Discovery Technology, 1996. 1(11): pp. 474-80.
199. Pisano, G.P., Searching for viable biobusiness models. Genetic engineering news, 2007. 27(8): pp. 6-8.
200. Bains, W., The Timetable of innovation. Drug Discovery World, 2006. 2006(2): pp. 3-12.
201. Sheridan, C., Diversa restructures, raising questions over bioprospecting. Nature Biotechnology, 2006. 24(3): p. 229.
202. Silverman, E., Who took the tech out of biotech. Nature Biotechnology, 2006. 24(3): pp. 255-6.
203. Morrow, K.J., Guaging nanobiotech's promise realistically. Genetic engineering news, 2006. 26(21): pp. 1-3.
204. Dorey, E., Skye pharma chair goes, 2006 Chemistry and Industry, 6 February 2006. p. 10.
205. Stone, M., Biotech venture capital examines itself. Nature Biotechnology, 1985. 3(2): pp. 110-13.
206. Jacobs, T., Bugs or drugs, tortoises or hares. Nature Biotechnology, 2005. 23(3): pp. 293.
207. Schafer, D.P., In-licensing as a business model. Nature Biotechnology, 2004. 20(Bioentrepreneur supplement): pp. BE36-BE9.
208. Hodgson, J., Validating a business model. Nature Biotechnology, 2000. 18(4): p. 378.
209. Anon (editorial), Hybrid rigor mortis. Nature Biotechnology, 2003. 21(6): p. 585.
210. Sedlak, B.J., Tool companies shift focus to pharma research. Genetic engineering news, 2002. 22(14): pp. 18-19.
211. Ratner, M., As products enter the clinic . scientists shown the door. Nature Biotechnology, 2004. 22(9): p. 1059.
212. Ransom, J., Niche indications could drive higher valuation. Nature Biotechnology, 2006. 24(12): p. 1457.
213. Ratner, M., Syrrx acquisition signams maturation of structure-based discovery. Nature Biotechnology, 2005. 23(4): p. 400.
214. Fletcher, L., Genomics companies shop around for chemical expertise. Nature Biotechnology, 2004. 22(2): pp. 137-8.
215. Petit-Zeman, S., Regenerative medicine. Nature Biotechnology, 2001. 19(3): pp. 201-6.
216. Gilson, R.J. and D.M. Schizer, Venture capital structure: A tax explanation for convertible preferred stock. Harvard Law Review, 2003. 116: pp. 875-916.
217. Berglof, E., A control theory of venture capital finance. Journal of Law, Economics & Organization, 1994. 10: pp. 247-67.
218. Cumming, D., Agency costs, institutions, learning and taxation in venture capital contracting. Journal of Business Venturing, 2005. 20(6): pp. 573-622.
219. Mirrlees, J.A., The theory of moral hazard and unobservable behaviour: Part I. Review of Economic Studies, 1999. 66: pp. 3-21.
220. Holmström, B., Moral hazard and observability. Bell Journal of Economics, 1979. 10(1): pp. 74-91.
221. Trester, J.J., Venture capital contracting under asymmetric information. Journal of Banking and Finance, 1998. 22(6-8): pp. 675-99.
222. Altman, L.S., Term sheet trends in the venture capital market http://www. nature.com/cgi-taf/gateway.taf?g=6&file=/bioent/building/financing/122003/ full/bioent785.html (produced by Nature Biotechnology Entrepreneurship, accessed 12/2/2005).
223. Stein, J.C., Convertible bonds as backdoor equity financing. Journal of Financial Economics, 1992. 15: pp. 3-29.
224. Shirley, P., Venture Capital. Fiscal Studies, 1994. 15(2): pp. 90-104.
225. Christoffersen, R., How to improve Series B-round valuations. Genetic engineering news, 2005. 25(19): pp. 22-5.
226. Cookson, C., Intercytex sees promise in wound healing, Financial Times (London), 8 August 2005, p. 22.
227. Friedli, D., I. Dey, and G. Dixon, That sinking feeling, Scotland on Sunday, (Edinburgh), 1 August 2004, p. 5.
228. Murray-West, R., Cyclacel pulls plug on float, Daily Telegraph, (London), 27 July 2004, p. 27.
229. Firn, D., Microscience calls of plans for AIM flotation, Financial Times, (London), 10 July 2004, p. 2.
230. Foley, S., Business analysis: Why the markets have fallen out of love with biotech companies, Independent, (London), 29th June 2005, p. 59.
231. Stout, K., Drivers of M&A: Implications for the UK Biotechnology industry, in Tanaka Business School. 2007, Imperial College: London.
232. Anon, Pride comes before a fall (and a bloodbath). Nature Biotechnology, 2002. 20(12): p. 1173.
233. Mitchell, P., UK Bidding war amid merger mania. Nature Biotechnology, 2003. 21(4): pp. 343-4.
234. van Brunt, J., Mergers were hot in 2005 www.signalsmag.com (produced by Recombinant Capital, accessed 22 May 2006).
235. Mitchell, P., UK Industry consolidation is slow despite big merger. Nature Biotechnology, 2003. 21(3): p. 215.
236. Lang, L.H.P. and R.M. Stulz, Tobin's q, corporate diversification, and firm performance. Journal of Political Economy, 1994. 102: pp. 1248-80.
237. Berger, P.G. and E. Ofek, Diversification's effect on firm value. Journal of Financial Economics, 1995. 37: pp. 39-65.
238. Comment, R. and G.A. Jarrell, Corporate focus and stock returns. Journal of Financial Economics, 1995. 37: pp. 67-87.
239. Servaes, H., The value of diversification during the conglomerate merger wave. Journal of Finance, 1996. 51: pp. 1201-25.
240. John, K. and E. Ofek, Asset sales and increase in focus. Journal of Financial Economics, 1995. 37: pp. 105-26.
241. Aggarwal, R.K. and A.A. Samwick, Why do managers diversify their firms? Agency reconsidered. Journal of Finance, 2003. 58(1): pp. 71-118.
242. Mansi, S.A. and D.M. Reeb, Corporate diversification: What gets discounted? Journal of Finance, 2002. 57(5): pp. 2167-84.
243. Ruffulo, R. Strategy for re-engineering dsicovery and development to address R&D productivity in Drug Discovery Technology Europe 2005. 2005. London, UK: Informa Ltd.
244. Jacobs, T., Does biotech M&A benefit investors? Nature Biotechnology, 2004. 22(9): p. 1085.
245. Meeks, G., Disappointing marriage: A study of the gains from merger. Occasional Paper 51, Department of Applied Economics, Cambridge. 1977, University of Cambridge, Department of Applied Economics (Cambridge, UK, 1977).
246. Maybeck, V., Motives and Mergers as drivers for change in the business model, in Institute of Biotechnology. 2005, Cambridge: Cambridge, UK.
247. Maybeck, V. and W. Bains, Small company mergers - a good idea for whom? Nature Biotechnology, 2006. 24(11): pp. 1343-8.
248. Esposito, R.S. and M.J. Ostro, Strategic consolidation: The biotechnology business model for the 21st century. Nature Biotechnology, 1999. 17(Supplement): pp. BE16-BE17.
249. Colyer, A., Financing as a driver for mergers and acquisitions. Nature Biotechnology, 1999. 17(Supplement): p. BE13.
250. Amihud, Y. and B. Lev, Risk reduction as a managerial motive for conglomerate mergers. The Bell Journal of Economics, 1981. 12(2): pp. 605-17.
251. Åstebro, T., Basic statistics on the success rate and profits for independent inventors. Entrepreneurship Theory and Practice, 1998. 23(2): pp. 41-8.
252. Jensen, D.G., Novel model for biotech cluster development. Genetic engineering news, 2004. 24(16): pp. 1, 14-15.
253. Lindelhöf, P. and H. Löfsten, Growth, management and financing of new technology- based firms - assess value-added contributions of firms located on and off Science Parks. Omega, 2002. 30: pp. 143-54.
254. Forbes, D.P., Are some entrepreneurs more overconfident than others? Journal of Business Venturing, 2005. 20: pp. 623-40.
255. Graham, P., How to start a start-up http://www.paulgraham.com/start.html (produced by Paul Graham, accessed 24 March 2005).
256. Andrews, A.O. and T.M. Welbourne, The people/performance balance in IPO firms: The effect of the chief executive officer's financial orientation. Entrepreneurship Theory and Practice, 2000. 25(1): pp. 93-106.
257. Birley, S. and P. Westhead, A comparison of new businesses established by 'novice' and 'habitual' founders in Great Britain. International Small Business Journal, 1993. 12(1): pp. 38-57.
258. Westhead, P. and M. Wright, Novice, portfolio and serial founders: Are they different? Journal of Business Venturing, 1998. 13: pp. 173-204.
259. Busenitz, L.W., J.O. Fiet, and D.D. Moesel, Signalling in venture capitalist-new venture team funding decisions: Does it indicate long-term venture outcomes? International Small Business Journal, 2005. 29(1): pp. 1-12.
260. North, J., J. Curran, and R. Blackburn, Quality and small firms: A policy mismatch and its impact on small enterprises, in Small firms: Entrepreneurship in the nineties, D. Deakins, P. Jennings, and C. Mason, eds 1997, Paul Chapman Publishing: London. pp. 112-26.
261. Sun, H. and T. -K. Cheng, Comparing reasons, practices and effects of ISO9000 certification and TQM implementation in Norwegian SMEs and large firms. International Small Business Journal, 2002. 20(4): pp. 421-42.
262. Storey, D.J., Exploring the link, among small firms, between management training and firm performance: A comparison between the UK and other OECD countries. International Journal of Human Resource Management, 2004. 15(1): pp. 112-30.
263. Elton, E.J., M.J. Gruber, and C.R. Blake, Incentive Fees and Mutual Funds. Journal of Finance, 2003. 58(2): pp. 779-804.
264. Cumming, D., G. Fleming, and J.-A. Suchard, Venture capitalist value-added activities, fundraising and drawdowns. Journal of Banking and Finance, 2005. 29(2): pp. 295-331.
265. Anon, 50 million dollars for leap into bio-tech, Times, (London), 24th May 1987, p. 3.
266. Fallon, I., Bio-raidable, Sunday Times, (London), 1 July 1990, p. 1.
267. Chong, L., Goldman staff share $16bn in bonus bonanza, Times, (London), 12 December 2006, p. 1.
268. Bawden, T., Lehman and Bear Stearns join banking bonus boom, Times, (London), 15 December 2006, p. 3.
269. Ang, J., B. Lauterbach, and B.Z. Schreiber, Pay at the executive suite: How do US banks compensate their top management teams? Journal of Banking and Finance, 2002. 26(6): pp. 1143-63.
270. Balboa, M. and J. Martí, Factors that determine the reputation of private equity managers in developing markets. Journal of Business Venturing, 2007. 22(4): pp. 453-480.
271. Stewart, T.A., Corporate social responsibility: Getting the logic right. Harvard Business Review, 2006. 2006(December): p. 14.
272. Frank, L., T. Tschernine, and F. Schöhharting, Venture capital with a European twist. Nature Biotechnology, 1999. 17(Supplement): pp. BE23-24.
273. Ross, S.A., The economic theory of agency: The Principal's problem. American Economic Review, papers and proceedings, 1973. 63(2): pp. 134-9.
274. Jeng, L.A. and P.C. Wells, The determinants of venture capital funding: Evidence across countries. Journal of Corporate Finance, 2000. 6: pp. 241-89.
275. Koberstein, W. and K. Robinson, The secure IPO launch plan, in BioExecutive International. 2005. pp. 59-67.
276. Bergemann, D. and U. Hege, Venture financing, moral hazard, and learning. Journal of Banking and Finance, 1998. 22(6-8): pp. 703-35.
277. Silverman, E., The hermit crab solution. Nature Biotechnology, 2006. 24(3): pp. 245-7.
278. Gompers, P.A., Grandstanding in the venture capital industry. Journal of Financial Economics, 1996. 42: pp. 133-56.
279. Lee, P.M. and S. Wahal, Grandstanding, certification and the underpricing of venture capital backed IPOs. Journal of Financial Economics, 2004. 73: pp. 375-407.
280. Neus, W. and U. Walz, Exit timing of venture capitalists in the course of an initial public offering. Journal of Financial Intermediation, 2005. 14: pp. 253-77.
281. Durman, P., Biotechs 'not ready' to float, Sunday Times, (London), 23 May 2004, p. 3.
282. Wang, C.K., K. Wang, and Q. Lu, Effects of venture capitalists' participation in listed companies. Journal of Banking and Finance, 2003. 27(10): pp. 2015-34.
283. Jain, B. and O. Kini, Venture capitalists participation and the post-issue operating performance of IPO firms. Managerial and Decision Economics, 1995. 16: pp. 593-606.
284. Warren, W.J., University start-up licensing tactics. Genetic engineering news, 2004. 24(21): pp. 20-2.
285. Parker, R., The myth of the entrepreneurial economy: Employment, innovation and small firms. Work Employment and Society, 2002. 15(2): pp. 373-84.
286. Lambert, R., Lambert Review of Business-University Collaboration: Final report. 2003, HMSO (London, UK).
287. Storey, D.J. and S. Johnson, Are small firms the answer to unemployment? 1987, Employment Institute (London, 1987).
288. Birch, D., The job creation process. 1979, M.I.T. programme on neighborhood and regional change (Cambridge, MA, 1979).
289. Marlow, S., Commentary on Parker. International Small Business Journal, 2002. 20: p. 111-2.
290. Ross, H., Supporting High Technology start-ups: The Scottish experience, in New technology-based firms in the new millennium, W. During, R. Oakey, and M. Kipling, eds 2000, Permagon: Oxford. pp. 8-15.
291. Michael, A., Financing doubts surround hundreds of German companies. Nature Biotechnology, 1997. 15(12): pp. 1334-5.
292. Fürst, I., Concern mounts over Munich's BioRegio money. Nature Biotechnology, 1998. 16(7): pp. 614-15.
293. Fürst, I., Boom to doom for German biotech? Nature Biotechnology, 1998. 16(11): p. 997.
294. Turok, I., Disconnected measures: European structural fund support for small business, in Small Firms: Entrepreneurship in the Nineties, D. Deakins and P. Jennings, eds 1998, Paul Chapmen Publishing: London. pp. 141-61.
295. Giles, J., Tax change curtails UK University spin-offs. Nature, 2004. 429: p. 6.
296. Cullen, K., UNICO - measuring change and making a difference in the UK, in From IP to IPO: Key issues in commercialising university technology (Supplement to Intellectual Property Management magazine), J. Wild, ed. 2005, Intellectual Property Management magazine: London. pp. 11-12.
297. Cumming, D., The structure, governance and performance of UK Venture Capital Trusts. Journal of Corporate Law Studies, 2003. 3(2): pp. 401-27.
298. DTI, Trade and Industry - Thirteenth Report. 2003, Department of Trade and Industry (London, 9 May 2003).
299. OST, The University Challenge Fund guidelines - outline application stage. 1998, Office of Science and Technology, Department of Trade and Industry (London, 1/3/1998).
300. Hewitt, P., Answer to parliamentary question. 2003, Hansard: London. p. 331W.
301. Johnstone, H., Equity gaps in depleted communities, in New technology-based firms in the new millennium, W. During, R. Oakey, and M. Kipling, eds 2000, Permagon: Oxford. pp. 84-94.
302. Bottazzi, L. and M. Da Rin, Venture capital in Europe and the financing of innovative companies. Economic Policy, 2002. 17(34): pp. 229-70.
303. Lynn, J. and A. Jay, Yes, Prime Minister, vol II, pp 130-1. 1987, London: BBC Books.
304. Anon, Blair calls for 'big push' for UK biotech industry, in SCRIP World Pharmaceutical News. 2007. p. 3.
305. Aernoudt, R., European policy towards venture catital: Myth or reality? Venture Capital, 1999. 1(1): pp. 47-58.
306. Enserink, M., France hatches 67 California wannabes. Science, 2005. 309(5734): p. 547.
307. NAPF, Institutional Investment in the UK Six Years On. 2007, National Association of Pension Funds (London, January 2007).
308. Washburn, J., University Inc. The corporate corruption of higher education. 2004.
309. Patten, C., Europe pays the price for spending less. Nature, 2006. 441(7094): pp. 691-3.
310. DeFrancesco, L., Company founders: Voices of experience http://www.nature. com/nbt (produced by Nature Biotechnology, accessed 1 April 2005).
311. Hollon, T., Aiming for the next winner http://www.signalsmag.com (produced by Signals Magazine, accessed 1 April 2005).
312. Bains, W., Fraud and Scandal in biotech. Nature Biotechnology, 2006. 24(7): pp. 745-7.
313. Evans, C., Building value in European biotech. 2002, IIR Conferences - presented material: IIR Biotechnology Conference, 19-20/11/2002, ExCeL Centre, London, UK.
314. Wong, A., Angel finance: The other venture capital (University of Chicago working paper). 2002: University of Chicago.
315. J. Robert Scott, WilmerHale, and Ernst & Young LLP, Compensation and Entrepreneurship Report in Life Sciences http://www.compstudy.com/LFdefault. aspx (produced by Harvard Business School, accessed 20 August 2006).
316. Feldbaum, C.B., A bill of rights for bioentrepreneurs. Nature Biotechnology, 1998. 16(Supplement): p. 18.